| pubmed-article:19917001 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19917001 | lifeskim:mentions | umls-concept:C0002986 | lld:lifeskim |
| pubmed-article:19917001 | lifeskim:mentions | umls-concept:C2754943 | lld:lifeskim |
| pubmed-article:19917001 | lifeskim:mentions | umls-concept:C2919019 | lld:lifeskim |
| pubmed-article:19917001 | lifeskim:mentions | umls-concept:C1519275 | lld:lifeskim |
| pubmed-article:19917001 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:19917001 | lifeskim:mentions | umls-concept:C0596530 | lld:lifeskim |
| pubmed-article:19917001 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:19917001 | pubmed:dateCreated | 2009-11-17 | lld:pubmed |
| pubmed-article:19917001 | pubmed:abstractText | To report a severe adverse event related to enzyme replacement therapy with agalsidase in an hemizygous male patient treated for Fabry disease. | lld:pubmed |
| pubmed-article:19917001 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19917001 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19917001 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19917001 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19917001 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19917001 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19917001 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19917001 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19917001 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19917001 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19917001 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:19917001 | pubmed:issn | 1365-2125 | lld:pubmed |
| pubmed-article:19917001 | pubmed:author | pubmed-author:LidoveOlivier... | lld:pubmed |
| pubmed-article:19917001 | pubmed:author | pubmed-author:PapoThomasT | lld:pubmed |
| pubmed-article:19917001 | pubmed:author | pubmed-author:ArnaudPhilipp... | lld:pubmed |
| pubmed-article:19917001 | pubmed:author | pubmed-author:TesmoingtChlo... | lld:pubmed |
| pubmed-article:19917001 | pubmed:author | pubmed-author:NicaisePascal... | lld:pubmed |
| pubmed-article:19917001 | pubmed:author | pubmed-author:RebergaAxeleA | lld:pubmed |
| pubmed-article:19917001 | pubmed:author | pubmed-author:ThetisMarguer... | lld:pubmed |
| pubmed-article:19917001 | pubmed:author | pubmed-author:AckaertChloeC | lld:pubmed |
| pubmed-article:19917001 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19917001 | pubmed:volume | 68 | lld:pubmed |
| pubmed-article:19917001 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19917001 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19917001 | pubmed:pagination | 765-9 | lld:pubmed |
| pubmed-article:19917001 | pubmed:dateRevised | 2010-11-2 | lld:pubmed |
| pubmed-article:19917001 | pubmed:meshHeading | pubmed-meshheading:19917001... | lld:pubmed |
| pubmed-article:19917001 | pubmed:meshHeading | pubmed-meshheading:19917001... | lld:pubmed |
| pubmed-article:19917001 | pubmed:meshHeading | pubmed-meshheading:19917001... | lld:pubmed |
| pubmed-article:19917001 | pubmed:meshHeading | pubmed-meshheading:19917001... | lld:pubmed |
| pubmed-article:19917001 | pubmed:meshHeading | pubmed-meshheading:19917001... | lld:pubmed |
| pubmed-article:19917001 | pubmed:meshHeading | pubmed-meshheading:19917001... | lld:pubmed |
| pubmed-article:19917001 | pubmed:meshHeading | pubmed-meshheading:19917001... | lld:pubmed |
| pubmed-article:19917001 | pubmed:meshHeading | pubmed-meshheading:19917001... | lld:pubmed |
| pubmed-article:19917001 | pubmed:meshHeading | pubmed-meshheading:19917001... | lld:pubmed |
| pubmed-article:19917001 | pubmed:meshHeading | pubmed-meshheading:19917001... | lld:pubmed |
| pubmed-article:19917001 | pubmed:meshHeading | pubmed-meshheading:19917001... | lld:pubmed |
| pubmed-article:19917001 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19917001 | pubmed:articleTitle | Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies. | lld:pubmed |
| pubmed-article:19917001 | pubmed:affiliation | Department of Clinical Pharmacy, Bichat-Claude Bernard University Hospital (AP-HP), Paris, France. | lld:pubmed |
| pubmed-article:19917001 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19917001 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19917001 | lld:pubmed |
